NCT01921387View on ClinicalTrials.gov

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 9, 2013

Primary Completion Date

July 26, 2017

Study Completion Date

July 26, 2020

Conditions
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Hodgkin LymphomaRecurrent Mantle Cell LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Hodgkin LymphomaRefractory Mantle Cell LymphomaRefractory T-Cell Non-Hodgkin Lymphoma
Interventions
PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo autologous PBSC transplant

DRUG

Carmustine

Given IV

DRUG

Cytarabine

Given IV

DRUG

Etoposide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan

Given IV

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo autologous PBSC transplant

RADIATION

Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT01921387 - Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies | Biotech Hunter | Biotech Hunter